



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: <b>1662/546051</b>	
Application Number <b>10/669,272</b>	Filing Date <b>September 23, 2003</b>	Examiner <b>Not Yet Assigned</b>	Art Unit <b>1614</b>
Invention Title <b>PREPARATION OF RISPERIDONE</b>		Inventors <b>KROCHMAL, et al.</b>	

Address to:  
Mail Stop: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.

5. Please debit Deposit Account No. **11-0600** in the amount of **\$180.00** in payment of the fee under 37 CFR §1.17(p) to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 CFR §1.97(c)(2).

Dated: June 2, 2006

By:

King L. Wong  
King L. Wong (Reg. No. 37,500)

KENYON & KENYON LLP  
One Broadway  
New York, New York 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)  
CUSTOMER NUMBER 26646



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	ATTY. DOCKET NO. 1662/546051	SERIAL NO. 10/669,272
	APPLICANT KROCHMAL, et al.	
	FILING DATE September 23, 2003	GROUP 1614

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	ES 2 050 069	May 1, 2004	Spain			X	
	ES 2 074 966	September 16, 2005	Spain			X	
	WO 01/85731 A1	November 15, 2001	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	